1363386-57-5

Basic information

• Product Name: 2-(6-Isobutoxy-naphthalen-2-yl)-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane
• Synonyms: 2-(6-Isobutoxy-naphthalen-2-yl)-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane
• CAS NO: 1363386-57-5
• Molecular Formula: C20H27BO3
• Molecular Weight: 326.23758
• EINECS: 940-986-8
• Mol File: 1363386-57-5.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 447.0±18.0 °C(Predicted)
• Appearance: /
• Density: 1.05±0.1 g/cm3(Predicted)
• CAS DataBase Reference: 2-(6-Isobutoxy-naphthalen-2-yl)-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(6-Isobutoxy-naphthalen-2-yl)-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane(1363386-57-5)
• EPA Substance Registry System: 2-(6-Isobutoxy-naphthalen-2-yl)-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane(1363386-57-5)

Safety Data

• Hazardous Substances Data: 1363386-57-5(Hazardous Substances Data)

Usage

Molecular structure

Complex, contains boron, oxygen, carbon, and hydrogen atoms.

Classification

Boronic acid.

Usage

Organic synthesis, potential applications in pharmaceuticals, agrochemicals, and materials science.

Functional groups

Unique boron-containing functional groups, naphthalen-2-yl and isobutoxy groups.

Properties

Valuable for the development of new chemical reactions, versatile precursor in the synthesis of various organic compounds, contributes to stability and solubility.

Upstream product

• 1363386-56-4 2-bromo-6-isobutoxynaphthalene 
• 73183-34-3 bis(pinacol)diborane 
• 15231-91-1 6-bromo-naphthalen-2-ol 

Relevant articles and documents

Development of Toxoplasma gondii calcium-dependent protein kinase 1 (Tg CDPK1) inhibitors with potent anti- toxoplasma activity

Toxoplasmosis is a disease of prominent health concern that is caused by the protozoan parasite Toxoplasma gondii. Proliferation of T. gondii is dependent on its ability to invade host cells, which is mediated in part by calcium-dependent protein kinase 1 (CDPK1). We have developed ATP competitive inhibitors of TgCDPK1 that block invasion of parasites into host cells, preventing their proliferation. The presence of a unique glycine gatekeeper residue in TgCDPK1 permits selective inhibition of the parasite enzyme over human kinases. These potent TgCDPK1 inhibitors do not inhibit the growth of human cell lines and represent promising candidates as toxoplasmosis therapeutics.